Summary
Currently, there are no vaccines against HIV (human immunodeficiency virus) and HSV (herpes simplex virus) infections. Condom, when used properly, are the most effective means of prophylaxis against viral transmission. However, there is a significant gender imbalance in condom use because women are not always in control over their use. In addition, women are at least twice as likely as men to contract sexually transmitted infections (STIs) from infected partners. Several STIs, including HIV, are underdiagnosed due to asymptomatic infections and/or lack of testing facilities. This is particularly problematic for women from African countries, who are at high risk of contracting STIs but have poor access to testing facilities. Alternatives to condoms that use established antivirals for HIV prophylaxis come with issues such as antimicrobial resistance and low adherence in practice in high-risk groups. There are also no means other than condoms for prophylaxis against HSV. Co-infection with HIV/HSV results in a vicious cycle of mutual facilitation, as individuals who are carriers of HSV have a three- to fourfold increased risk of contracting HIV. Inspired by nature, NatProLub develops a radically novel prophylactic approach to HIV and HSV prophylaxis through the use of lubricants. By targeting women, who are particularly at risk, NatProLub has a clear vision for a user-friendly, prophylactic product that can redress the gender imbalance in sexual health while offering a low risk of side effects and avoiding the risk of developing antimicrobial resistance. The members of the NatProLub consortium have very strong backgrounds in relevant but complementary scientific disciplines that will contribute to the development of prophylactic lubricants for end users and have previous successful experience in managing large scientific projects, the creation of spin-off companies, and maintaining well-developed professional networks in academia, industry, and healthcare.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101130633 |
| Start date: | 01-01-2024 |
| End date: | 31-12-2027 |
| Total budget - Public funding: | 2 998 788,75 Euro - 2 998 788,00 Euro |
Cordis data
Original description
Currently, there are no vaccines against HIV (human immunodeficiency virus) and HSV (herpes simplex virus) infections. Condom, when used properly, are the most effective means of prophylaxis against viral transmission. However, there is a significant gender imbalance in condom use because women are not always in control over their use. In addition, women are at least twice as likely as men to contract sexually transmitted infections (STIs) from infected partners. Several STIs, including HIV, are underdiagnosed due to asymptomatic infections and/or lack of testing facilities. This is particularly problematic for women from African countries, who are at high risk of contracting STIs but have poor access to testing facilities. Alternatives to condoms that use established antivirals for HIV prophylaxis come with issues such as antimicrobial resistance and low adherence in practice in high-risk groups. There are also no means other than condoms for prophylaxis against HSV. Co-infection with HIV/HSV results in a vicious cycle of mutual facilitation, as individuals who are carriers of HSV have a three- to fourfold increased risk of contracting HIV. Inspired by nature, NatProLub develops a radically novel prophylactic approach to HIV and HSV prophylaxis through the use of lubricants. By targeting women, who are particularly at risk, NatProLub has a clear vision for a user-friendly, prophylactic product that can redress the gender imbalance in sexual health while offering a low risk of side effects and avoiding the risk of developing antimicrobial resistance. The members of the NatProLub consortium have very strong backgrounds in relevant but complementary scientific disciplines that will contribute to the development of prophylactic lubricants for end users and have previous successful experience in managing large scientific projects, the creation of spin-off companies, and maintaining well-developed professional networks in academia, industry, and healthcare.Status
SIGNEDCall topic
HORIZON-EIC-2023-PATHFINDEROPEN-01-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Search
Organisations
